Stock Analysis
NewAmsterdam Pharma Company N.V. (NAMS) Stock Analysis
NewAmsterdam Pharma Company N.V. (NAMS) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
NewAmsterdam Pharma Company N.V. (NAMS) currently has an AIQ Score of 41/100, indicating a bearish setup. Quality is the strongest factor at 58/100. Momentum is the weakest current factor at 22/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
NAMS at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $20.14 |
| AIQ Score | 41/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Neutral |
| Market Cap | $2.5B |
| P/E Ratio (TTM) | -11.78 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.14 |
| Revenue (Q3 FY2026) | $19.16M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.43 |
| Volume | 1.67M |
| 52-week range | $17.90-$42.21 |
| RSI 14 | 47.28 |
| 50-Day SMA | $21.53 |
| 200-Day SMA | $29.16 |
| Analyst Price Target | $61.00 |
| Next Earnings | Feb 17, 2027 |
NAMSNewAmsterdam Pharma Company N.V.
Healthcare / Biotechnology
Low Priority
Relative Laggard
Latest quote
- Momentum22
- Value42
- Quality58
- Risk resilience48
- Sentiment—
NAMS Stock Analysis Summary
NewAmsterdam Pharma Company N.V. (NAMS) currently has an AIQ Score of 41/100, indicating a bearish setup. Quality is the strongest factor at 58/100. Momentum is the weakest current factor at 22/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, NAMS has AIQ Score of 41/100 with Quality base of 58/100 and fading Momentum at 22/100. Wait for component alignment before adding exposure.
Quality (58/100) leads while Momentum (22/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · 0.85% stock move · NAMS classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is NAMS Bullish or Bearish Right Now?
NAMS currently has a bearish overall setup. Quality is the strongest factor at 58/100, while Momentum is weakest at 22/100. The current evidence suggests a bearish setup.
- - Analyst target implies +202.88% upside from the latest quote.
- - Value is the current constraint at 42/100.
- - Momentum is weak at 22/100.
- - Risk Resilience is weak at 48/100.
- - Price is -30.92% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (22 vs 16).
Current Consensus
NAMS's Technical Analysis Consensus is currently Neutral, with 16 buy, 8 neutral, and 22 sell votes. NAMS's 14-day RSI is 47.28, which places the stock in a neutral momentum range. NAMS's beta is 1.43, indicating greater market sensitivity than the broad market.
What Changed in NAMS?
The largest recent change in NAMS is Momentum moving up by 4.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the NAMS Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
NAMS Decision Framework
Public evidence layers, setup checks, and risk context for NewAmsterdam Pharma Company N.V..
NewAmsterdam Pharma Company N.V. (NAMS) Stock Analysis
NewAmsterdam Pharma Company N.V. has an AIQ Score of 41/100 in a Bearish regime. Quality is strongest at 58/100. Beta is 1.43, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | NAMS is in a Bearish AIQ regime with score 41/100. |
| Signal Conflict | The primary conflict is that quality leads at 58/100 while momentum lags at 22/100. |
| Factor Evidence | Momentum 22/100 · Value 42/100 · Quality 58/100 · Risk 48/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 58/100.
Momentum is 22/100 and RSI (14) is 47.3.
NAMS is in a Bearish regime at 41/100.
Risk factor is 48/100 with beta 1.43 and annual volatility 53.82%.
Current conflict: quality leads at 58/100 while momentum lags at 22/100.
NAMS Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
NAMS Fundamentals
NAMS valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
NAMS Technical Analysis
NAMS technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
NAMS Stock Catalysts
Track NAMS earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
NAMS Dividend Analysis
NAMS dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
NAMS Financial Data
NAMS revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
NAMS Risk Analysis
NAMS volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
NAMS Stock News
NAMS stock news, market tone, recent headlines, and catalyst context.
NAMS vs Biotechnology Peers
Current peer cohort: NAMS · NBIX · NKTR · NRIX · NVAX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| NAMS Current stock | 41/100 | 42/100 | 22/100 | 48/100 | -0.91 | 53.82% | Current |
| NBIX Neurocrine Biosciences, Inc. | 74/100 | 77/100 | 70/100 | 69/100 | 0.49 | 35.22% | NAMS vs NBIX |
| NKTR Nektar Therapeutics | 39/100 | 47/100 | 25/100 | 41/100 | -0.11 | 84.03% | NAMS vs NKTR |
| NRIX Nurix Therapeutics, Inc. | 65/100 | 94/100 | 50/100 | 40/100 | 0.64 | 67.30% | NAMS vs NRIX |
| NVAX Novavax, Inc. | — | — | 77/100 | 38/100 | 0.56 | 73.62% | NAMS vs NVAX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for NAMS: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching NAMS
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for NAMS
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
NAMS Stock FAQ
What is NAMS stock price today?
NewAmsterdam Pharma Company N.V.'s current stock price is $20.14. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is NAMS bullish or bearish right now?
NAMS's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is NAMS's market cap?
NAMS's market cap is $2.5B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is NAMS's current P/E ratio?
NAMS's current P/E ratio is -11.78 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is NAMS's RSI?
NAMS's 14-day RSI is 47.28 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is NAMS above its 50-day and 200-day moving averages?
NAMS is -6.44% from its 50-day SMA and -30.92% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is NAMS's next earnings date?
NAMS's next earnings date is currently listed as Feb 17, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does NAMS pay a dividend?
NAMS's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.